Angiozyme

nuclease-stabilized ribozyme with phosphorothioate linkages developed against VEGF-receptor subtype Flt-1 mRNA for use as an angiogenesis inhibitor; base sequence given in first source

Networked: 6 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Weng, David E: 2 articles (09/2012 - 06/2005)
2.	Lockridge, Jennifer A: 2 articles (10/2005 - 06/2005)
3.	Usman, Nassim: 2 articles (10/2005 - 06/2005)
4.	Elias, Anthony D: 1 article (09/2012)
5.	Ensor, Joe D: 1 article (09/2012)
6.	Gordon, Gilad S: 1 article (09/2012)
7.	Hortobagyi, Gabriel N: 1 article (09/2012)
8.	Margolin, Kim A: 1 article (09/2012)
9.	Morrow, Phuong Khanh: 1 article (09/2012)
10.	Murthy, Rashmi K: 1 article (09/2012)

Related Diseases

1.	Rectal Neoplasms (Rectal Cancer) 08/01/2005 - "Whether the antitumoral efficacy of bevacizumab could be increased when combined to low-dose (metronomic) chemotherapy, or radiotherapy (in rectal cancer), is under development, as well other VEGF-targeted approaches (e.g., dominantnegative mutants, antisense oligonucleotides, antibodies directed against VEGF receptors (VEGFR), VEGFR tyrosine kinase inhibitors, soluble VEGFR,...), or other anti-angiogenesis agents (e.g., thalidomide, celecoxib, angiozyme...)."
2.	Neoplasms (Cancer) 03/01/2001 - "Clinical trials of Angiozyme are currently in progress for patients with advanced malignancy. " 10/01/2000 - "Because the stimulation of this receptor may contribute to tumor neovascularization and subsequent tumor growth and metastasis, we have explored the systemic use of ANGIOZYME to down regulate this receptor in a syngeneic model of metastatic cancer. " 03/01/2001 - "In animal tumor models, antitumor effects are most pronounced with the anti-Flt-1 ribozyme known as Angiozyme (Ribozyme Pharmaceuticals, Boulder, CO). " 10/01/2005 - "Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors." 06/01/2005 - "Surrogate markers showed Angiozyme localization in tumor biopsies and a significant increase in serum von Willebrand factor antigen, a marker for endothelial cell dysfunction. "
3.	Breast Neoplasms (Breast Cancer) 09/01/2012 - "An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer."
4.	Neoplasm Metastasis (Metastasis) 10/01/2000 - "Because the stimulation of this receptor may contribute to tumor neovascularization and subsequent tumor growth and metastasis, we have explored the systemic use of ANGIOZYME to down regulate this receptor in a syngeneic model of metastatic cancer. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
3.	Antisense Oligonucleotides
4.	Thalidomide (Thalomid)
5.	Antibodies
6.	Tyrosine Kinase Inhibitors
7.	Celecoxib (Celebrex)
8.	Bevacizumab (Avastin)
9.	Catalytic RNA (Ribozymes)
10.	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)

Related Therapies and Procedures

1.	Radiotherapy
2.	Drug Therapy (Chemotherapy)